Actively Recruiting
Study on Pixel CO2 Laser FemiLiftTM Treatment for Vulvo-Vaginal Atrophy in Women Aged 45 to 75
Led by Hillel Yaffe Medical Center · Updated on 2025-06-17
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Vulvo Vaginal Atrophy VVA is a condition affecting the vaginal and vulvar areas during menopause due to decreasing estrogen levels, causing symptoms such as dryness, irritation, soreness, pain during sex, painful urination, and discharge. This trial investigates the effects of a fractional microablative CO2 laser treatment called Pixel CO2 Laser FemiLiftTM to assess its impact on clinical symptoms and molecular changes in the vaginal tissue. Participants will receive treatment with the Pixel CO2 Laser device aimed at regenerating the vaginal epithelium and connective tissues. The laser treatment is designed to restore the vaginal lining to a state resembling that before menopause, indicated by thicker epithelium, increased collagen, glycogen, fibroblasts, vascularity, and other tissue improvements. The study focuses on evaluating these effects over a two-year period. During the study, researchers will monitor patient symptoms and complaints related to VVA and evaluate gene expression changes following treatment. Assessments will include gynecological exams, symptom tracking, and laboratory tests such as urine analysis and Pap smears as needed. Participants will be followed for two years to observe outcomes and safety while adhering to the treatment and follow-up schedules.
CONDITIONS
Brief Title
Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy
Research Team
J
Jonia Alsheik, MD
O
Osnat Palgi mirochnik, RN, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here